Severe abdominal pain followed by inappropriate antidiuretic hormone secretion (SIADH) preceding by several days the skin manifestation of varicella-zoster virus (VZV) infection in an immunocompromised patient is described. This is a rare presentation of a severe infection described previously only once in a chronic myeloid leukemia (CML) patient 5 months post allo-BMT during immunosuppressive treatment with cyclosporin A. This is the first case described in the setting of nonmyeloablative preparation with fludarabine and melphalan and followed by donor leukocyte infusion (DLI) 2 and 4 months post allo-BMT. The influence of these factors on development of VZV virus infection is discussed. We also highlight the high incidence and high mortality in VZV infection in immunocompromised patients as well as the frequent atypical presentation. Bone Marrow Transplantation (2000) 26, 231-233. Keywords: inappropriate antidiuretic hormone secretion; varicella-zoster virus infection; abdominal pain; bone marrow transplantation
A 57-year-old man was admitted to Royal Adelaide Hospital with a 2 day history of severe abdominal pain accompanied by nausea, vomiting and constipation. The patient had received an allogeneic peripheral blood stem cell transplant for CML 6 months prior to this admission and had been prepared with a non-myeloablative protocol. A combination of fludarabine 30 mg/m 2 i.v. for 5 days (days −6 to −2) and melphalan 140 mg/m 2 on day −1 was used as preparation before the transplant. Mobilized CD34 + cells/kg, respectively) according to the protocol. The patient did not develop GVHD. He was well until the day of admission, when suddenly, severe abdominal pain developed in association with nausea, vomiting and constipation. On admission the patient was afebrile, the abdomen was distended and tender and bowel sounds were diminished. The liver and spleen were not palpable. Liver function tests, serum amylase and serum lipase were within normal ranges. Plain abdominal X-ray showed dilated large bowel and some air-fluid levels in the small bowel, compatible with ileus. A gastrograffin enema excluded bowel obstruction. Glycerine and oil enema resulted in a small quantity of stool being passed but only temporary improvement in the pain. On day 2 after admission it was noted that the serum sodium (seNa) and plasma osmolality (plOsm), having initially been normal, had both declined, to 120 mmol/l (normal range 137-145) and 243 mmol/l (normal range 265-285), respectively. Urine showed an increased sodium concentration (urNa), up to 164 mmol/l (significant above 40 mmol/l) and increased osmolality to 813 mosmol/l (significant above 300 mosmol/l). Blood pressure was elevated to 180/110. Thyroid and adrenal tests were within normal limits. Given these results a diagnosis of inappropriate antidiuretic hormone secretion (SIADH) was made. Fluid restriction was instituted (1000 ml a day) with slight improvement in biochemistry after 24 h. On day 9 after the onset of gastrointestinal symptoms and 5 days after the development of SIADH, typical lesions of disseminated VZV infection developed on the trunk and scalp. The vesicle scrapings were positive for varicella-zoster virus (with both rapid enzyme assay and cultures) and negative for Herpes simplex virus. Assays were performed as described by Kok (unpublished) for VZV and by Kok et al 1 for herpes simplex viruses. The pre-transplant virology screen showed that both patient and donor were VZV-IgG positive. The abdominal pain improved dramatically and bowel activity recovered (the first vesicles evolved in the evening and the abdominal pain improved by morning, spontaneously). Treatment with intravenous acyclovir (10 mg/kg three times/day for 5 days) was commenced and the patient continued with oral valaciclovir (1000 mg 8 h for another 3 days) after the lesions crusted (new lesions appeared for 5 days from the onset). Blood pressure returned to normal without antihypertensive therapy and the biochemistry also normalized. The patient was discharged on oral valaciclovir 500 mg twice a day.
Discussion
There is, to our knowledge, only one previous report of a similar unusual presentation of VZV infection preceded for several days by a clinical picture suggestive of ileus and SIADH in a patient post allo-BMT. Drakos et al 2 described a 35-year-old CML patient 5 months post allograft and receiving immunosuppressive treatment with CyA. During the course of the infection their patient developed an elevation in liver enzymes as well as pancytopenia.
There are some unique features that distinguish our case from the above. Our patient had non-myeloablative conditioning with fludarabine and melphalan and received two doses of DLI before the VZV infection developed. The impact of fludarabine on host immunity is well known. It causes suppression of both cellular and humoral immunity, suppression of CD4 + and CD8 + T cells being most marked and recovery occurring slowly. 3 There is little known about the influence of non-myeloablative conditioning treatment on immune reconstitution in allografted recipients. According to a recent study, reconstitution of the T cell compartment following transplant with non-myeloablative conditioning is rapid, more diverse and includes a higher proportion of naive T cells compared to allograft with T cell-depleted stem cells. DLI, used to induce GVHD, had no influence on this aspect. 4 This patient received T celldepleted PBSCT followed by doses of donor T cells at 2 and 4 months. In contrast to the above, his T cell numbers were low (CD4 + cells 0.15 × 10 9 /l, CD4/CD8 ratio 0.24). VZV infection is a frequent problem confronting clinicians involved in the management of immunocompromised patients. In a cohort of 294 ALL patients (age 0-15), 41 experienced VZV infection during treatment and of these, seven patients presented with severe abdominal pain a few days before the skin lesions evolved. Four of seven patients died. 5 Immune reconstitution takes about 12 months after bone marrow transplantation 6, 7 and is further delayed in allogeneic transplant recipients with chronic GVHD receiving immunosuppressive treatment. In a retrospective analysis of 236 children transplanted with autologous marrow, 54 (23%) patients experienced at least one episode of VZV infection at a median of 83 days (range 25-225 days) after the first transplant, and at a median of 52 days (range 4-133) after the second ABMT. There were 10 cases of chickenpox, 43 of typical herpes zoster infection and seven disseminated zoster infections. 8 Similar results were published recently by Bilgrami et al. 9 Moreover, in a large review of 1394 patients who received allogeneic or syngeneic bone marrow transplantation, Locksley et al 10 found allogeneic transplantation, GVHD and treatment with antithymocyte globulin-independent risk factors for VZV infection. In their cohort 80% of infections occurred within the first 9 month after transplant.
Long-term prophylactic administration of acyclovir is an option in the post-transplant period. In a randomized double-blind and placebo controlled trial of 6 months prophylaxis with acyclovir in BMT recipients, those who received acyclovir had fewer VZV infections during the prophylaxis. However, no difference was found in the number of VZV infection between the two groups during the first year after BMT.
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Treatment with acyclovir or valaciclovir should be instituted immediately once the diagnosis is clear. [12] [13] [14] This may reduce mortality. However, in disseminated VZV infection the mortality is still very high. 15 We present a case in which the VZV infection was associated with severe abdominal pain and SIADH. The cause and mechanism of inappropriate secretion of ADH is unknown, but viral encephalitis may be responsible for stimulation of ADH release from the neurohypophyseal system. 2, 16, 17 In the absence of neurological symptoms lumbar puncture was not performed in our patient.
Serological tests to determine the presence of VZVspecific IgM antibodies are not useful in this clinical setting, as a negative test does not exclude VZV infection and a rise in IgM titre takes too long to develop. In contrast, the detection of VZV DNA in peripheral blood by PCR has been more recently recommended in patients with no rash but suspicion of VZV infection. 5, 18 Finally, it is important to emphasize again the possible connection between abdominal pain and VZV infection in immunocompromised patients. Because the infection in these patients carries a significant risk of mortality, antiviral treatment with acyclovir should be instituted as soon as other causes are excluded. This is the approach introduced by David et al 15 in their immunocompromised patients and it is also recommended by other authors. 5 PCR for VZV DNA detection in the peripheral blood and/or CSF should also be carried out, if possible, to enable early diagnosis and early antiviral treatment. 18 
